United Therapeutics reports Q1 EPS $6.17, consensus $5.65

Reports Q1 revenue $677.7M, consensus $623.97M. “Q1 represents another quarter of record revenue and double-digit year-over-year revenue growth,” jointly said CEO Martine Rothblatt and COO Michael Benkowitz. “That growth, coupled with our upcoming clinical reads, puts us in a unique position in the biotech industry: a company with a solid and growing commercial foundation, near-term clinical catalysts, and the potential to provide an unlimited supply of tolerable, transplantable organs.” “Our distinctive commercial and clinical profile, alongside our solid balance sheet and cash flow potential, makes United Therapeutics a compelling investment opportunity,” said CFO James Edgemond. “That’s why we implemented a $1B accelerated share repurchase that concretely demonstrates our belief in our near-term and long-term potential, despite potential competition emerging this year.”